The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

April 22, 2021

Study Completion Date

April 22, 2021

Conditions
Scleroderma
Interventions
BIOLOGICAL

Botulinum toxin(Botox)

This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.

Trial Locations (1)

75390-8802

UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT04523506 - The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma | Biotech Hunter | Biotech Hunter